How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

807 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease Full Text available with Trip Pro

galantamine treatment. Newer antipsychotics, including paliperidone, lurasidone, aripiprazole, ziprasidone, and BL-1020, have also been reported to exert cognitive benefits in patients with schizophrenia. Dopaminergic medications were found to improve language function in patients with Parkinson's disease. However, no beneficial effects on cognitive function were observed with dopamine agonists in patients with schizophrenia. The efficacies of nicotine and its receptor modulators in cognitive improvement

2018 Frontiers in Psychiatry

202. Profiling donepezil template into multipotent hybrids with antioxidant properties Full Text available with Trip Pro

Profiling donepezil template into multipotent hybrids with antioxidant properties Alzheimer's disease is debilitating neurodegenerative disorder in the elderly. Current therapy relies on administration of acetylcholinesterase inhibitors (AChEIs) -donepezil, rivastigmine, galantamine, and N-methyl-d-aspartate receptor antagonist memantine. However, their therapeutic effect is only short-term and stabilizes cognitive functions for up to 2 years. Given this drawback together with other

2018 Journal of enzyme inhibition and medicinal chemistry

203. An Open Pilot Trial of BHV-4157

is prohibited 30 days prior to screening and during the study; Use of aminopyridine is prohibited 30 days prior to screening and during the study; Use of tricyclic antidepressants and mono-amine-oxidase (MAO) inhibitors are prohibited 30 days prior to screening and during the study; Use of any approved treatments for Alzheimer's Disease (AD). Subjects should be free of such medications (donepezil, galantamine, rivastigmine and memantine) for at least 3 months prior to Baseline with no plans to start

2018 Clinical Trials

204. Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease Full Text available with Trip Pro

carried out virtual screening of drug-like molecules from Chemical Diversity Database particularly CNS-BBB compounds, to identify potential inhibitors using Glide docking program. Top ranking ten compounds, which have lower Glide Score when compared to known drugs (Tacrine and Galantamine) for AChE. For top three molecules MD simulation was carried out and calculated binding free energy. We report the best binding compounds with AChE compared to known drugs (Taine and Galantamine) for AD. We further (...) ligands Tacrine and Galantamine having -119.65 and -142.18 kJ/mol respectively. Thus these molecules can be very novel potential inhibitors against AChE involved in Alzheimer's disease.

2018 Bioinformation

205. Activation of α7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice Full Text available with Trip Pro

Activation of α7 Nicotinic Acetylcholine Receptor Ameliorates Zymosan-Induced Acute Kidney Injury in BALB/c Mice Zymosan, a natural compound, provokes acute peritonitis and multiple organ dysfunction that affects the kidney, beside other organs via exaggerated inflammatory response. The aim of the present study is to test the role of cholinergic anti-inflammatory pathway (CAP) in alleviating acute kidney injury (AKI) induced by zymosan in BALB/c mice, using galantamine, a cholinesterase (...) inhibitor, known to act via α7 nicotinic acetylcholine receptor (α7 nAChR) to stimulate CAP. Galantamine verified its anti-inflammatory effect by elevating acetylcholine (ACh) level, while abating the interleukin-6/ janus kinase 2 (Y1007/1008)/ signal transducer and activator of transcription 3 (Y705) (IL-6/ pY(1007/1008)-JAK2/ pY705-STAT3) inflammatory axis, with a consequent inhibition in suppressor of cytokine signaling 3 (SOCS3). This effect entails also the nuclear factor-kappa B (p65)/ high

2018 Scientific reports

206. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0

orbreasttissue.However,forcautioninthisrareinstanceandbecause of the potential for radiotracer excretion in human milk and potential radiation exposure to infants, either avoid performing amyloid PET imaging on a breastfeeding mother or have the mother interrupt breastfeeding for 24 h after administration of the 18 F radiotracer. There is no known evidence to suggest that there are drug interactions between amyloid radiotracers and common drugs pre- scribed for dementia patients, such as donepezil, galantamine

2016 European Association of Nuclear Medicine

207. Cholinesterase inhibitors to reduce the symptoms of Alzheimer's disease

Cholinesterase inhibitors to reduce the symptoms of Alzheimer's disease This document prepares the clinician to discuss scientific data with the patient so they can make an informed decision together. Presenting cholinesterase inhibitors to patients What are cholinesterase inhibitors for? Cholinesterase inhibitors (ChEIs) are medications taken daily to modify the symptoms of Alzheimer’s disease. These medications (donepezil, rivastigmine and galantamine) inhibit the breakdown of acetylcholine (...) description and references: 1. Birks. Cochrane Database Syst Rev 2006, CD 005593(1). Study design: systematic review of 13, multi-centre, randomized, double- blind parallel group trials comparing individuals treated with ChEIs (donepezil, galantamine and rivastigmine) versus placebo. Participants: 7,298 individuals from Europe, North America and Australia (mean age 73; range 49-94) with mild to severe dementia due to Alzheimer’s disease. Length of treatment: Minimum of 6 months. 2. AD 2000 Collaborative

2014 Cancer Council Australia

208. Help Versus Hope: Acetylcholinesterase Inhibitors in Alzheimer?s Disease

levels of care that often extend beyond the capabilities of family caretakers and result in high rates of patient placement in nursing homes. Preventing and reversing the dementia seen in AD in order to increase quality of life among these patients is the goal of treatment. Nevertheless, the backbone of Alzheimer’s treatment remains acetylcholinesterase inhibitors (CIs) such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). Memantine (Namenda), which is also approved (...) about the benefits of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease? Numerous studies investigating the effects of CI treatment on AD progression have yielded results that many find disappointing. One such study followed 2853 persons with Alzheimer’s disease to assess for changes in Mini-Mental State Examination (MMSE) score after treatment with donepezil, rivastigmine, or galantamine [8]. By 9 months, only 15.7% of patients responded to treatment, with two-thirds

2014 Clinical Correlations

211. Prescribing for older people with chronic renal impairment

Galantamine Benzodiazepines Atenolol Musculoskeletal Levetiracetam Bupropion Bisoprolol Allopurinol Memantine Desvenlafaxine Digoxin Bisphosphonates Methysergide Duloxetine Fenofibrate Colchicine Pramipexole Lithium Strontium ranelate Pregabalin Paliperidone Teriparatide Topiramate Reboxetine Varenicline Venlafaxine * This list does not include antibiotic, antifungal or antiviral medicines, or those medicines predominately used in the hospital setting # Not available on the PBS/RPBS † Use in renal

2013 Clinical Practice Guidelines Portal

213. Treatment of tardive syndromes

. Amantadine and tetrabenazine might be considered as TDS treatment (Level C). Diltiazem should not be considered as TDD treatment (Level B); galantamine and eicosapentaenoic acid may not be considered as treatment (Level C). Data are insufficient to support or refute use of acetazolamide, bromocriptine, thiamine, baclofen, vitamin E, vitamin B 6 , selegiline, clozapine, olanzapine, melatonin, nifedipine, fluperlapine, sulpiride, flupenthixol, thiopropazate, haloperidol, levetiracetam, quetiapine (...) drugs. Cholinergic drugs (including choline, lecithin, physostigmine, tacrine, donepezil, rivastigmine, deanol, meclofenoxate, and galantamine) have been tried in TDS treatment. One Class II study of galantamine in 35 patients with schizophrenia and TDS found that galantamine did not lessen TDS, e21 and there was evidence of increased parkinsonism. Conclusion. Galantamine is possibly ineffective in treating TDS (1 Class II study). Recommendations. Galantamine might not be considered in treating TDS

2013 American Academy of Neurology

214. Use it or Lose it- Do cognitive leisure activities protect against the development of Alzheimer?s?

suffering from Alzheimer’s disease. The disease is the fifth leading cause of death for adults aged 65 years and older, and is estimated to affect 1 in 8 persons in this age group.[1,2] Despite recent advances, the cause of Alzheimer’s disease is not well understood. The FDA-approved medications in common use—donepezil (Aricept), galantamine (Razadyne), rivastigmine (Exelon), and memantine (Namenda)–help to manage symptoms; however there are no treatments available shown to stop or reverse

2012 Clinical Correlations

216. Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching. (Abstract)

between donepezil, galantamine, oral rivastigmine, and rivastigmine patch.A population-based cohort study, using British Columbia claims data (2009-2013), assessed ChEI new users aged 40 and older. We conducted survival analysis to compare persistence and Poisson regression to estimate switching rates. Good adherence, defined as a medication possession ratio of ≥80%, was modeled using log-binomial regression. Analyses were adjusted using propensity scores.Patients on galantamine had longer mean (...) discontinuation compared with oral [hazard ratio 0.79 (95% CI 0.71-0.89)] and decreased switching [relative risk 0.63 (95% CI 0.46-0.87) during the first 6 months of treatment]. Paradoxically, the patch was also associated with poorer adherence [relative risk for good adherence 0.94 (95% CI 0.91-0.98)] than the oral formulation.Based on estimates of persistence, adherence, and switching, galantamine was the best tolerated ChEI and rivastigmine the least.

2017 Drugs & Aging

217. Potential benefits of phytochemicals against Alzheimer's disease. Full Text available with Trip Pro

Potential benefits of phytochemicals against Alzheimer's disease. Our current therapeutic drugs for Alzheimer's disease are predominantly derived from the alkaloid class of plant phytochemicals. These drugs, such as galantamine and rivastigmine, attenuate the decline in the cholinergic system but, as the alkaloids occupy the most dangerous end of the phytochemical spectrum (indeed they function as feeding deterrents and poisons to other organisms within the plant itself), they are often

2017 Proceedings of the Nutrition Society

218. Acetylcholinesterase inhibitor treatment alleviated cognitive impairment caused by delayed encephalopathy due to carbon monoxide poisoning: Two case reports and a review of the literature. Full Text available with Trip Pro

. This was evidenced by an improved Mini-Mental State Examination score ffom 9 to 28 points in Case 1 and an improved Hasegawa's dementia rating scale score from 4 to 25 points in Case 2 after administration of an AchEI. In Case 1, we administered galantamine hydrobromide, which was related with improved white matter lesions initially detected on brain magnetic resonance imaging. However, in Case 2 white matter lesions persisted despite AchEI treatment. AchEI treatment may result in improved cognitive and frontal

2017 Medicine

219. Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients

and other specific malignancies noted above, patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last five years or whose previous cancer treatment contraindicates this therapy are excluded. Patients with underlying dementia (or on medications to treat Alzheimer's disease such as donepezil, rivastigmine, galantamine, tacrine, or memantine), encephalopathy, or other neurological disorder known to adversely affect cognition (such as epilepsy

2017 Clinical Trials

220. A Study of LY3154207 in Participants With Parkinson's Disease Dementia

measurement must be less than 180 mmHg Participants ≥60 years old: A mean systolic BP less than or equal to 150 mmHg, a mean diastolic BP less than or equal to 90 mmHg and a mean pulse rate less than or equal to 90 beats/min in a seated position. Each of the 3 systolic BP measurement must be less than 180 mmHg If on anti-parkinsonian agents, participants must be on stable dosage for at least 4 weeks prior to baseline. If on medications affecting cognition (rivastigmine, galantamine, donepezil, memantine

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>